



ASX Announcement

17 March 2021

## Atomo to present at NWR Virtual Investor Conference

**SYDNEY Australia Wednesday, 17 March 2021** – Australian rapid blood test company Atomo Diagnostics Limited (ASX: AT1) (**Atomo**) is pleased to announce it will present at the NWR Virtual Investor Conference to be held on Thursday, 18 March 2021.

The Company invites shareholders and investors to see Atomo Diagnostics CEO John Kelly and CFO Will Souter present an update at 12:30pm (AEDT) on 18 March 2021.

**Event:** NWR Virtual Investor Conference

**Presenting:** Mr John Kelly (CEO, Atomo Diagnostics) and Mr Will Souter (CFO, Atomo Diagnostics)

**Time:** Thursday, 18 March 2021, 12:30pm (AEDT) for 25 minutes

Investors are invited to submit questions prior to the event to:

[simon@nwrcommunications.com.au](mailto:simon@nwrcommunications.com.au)

Investors can register online to view the presentation here:

[https://us02web.zoom.us/webinar/register/WN\\_vWcRVTYnT1qtWEXW-7O1GA](https://us02web.zoom.us/webinar/register/WN_vWcRVTYnT1qtWEXW-7O1GA)

For further information on the conference click here: <https://nwrconference.webflow.io/>

For more information, please contact:

Jane Lowe

IR Department

[jane.lowe@irdepartment.com.au](mailto:jane.lowe@irdepartment.com.au)

Phone: +61 411 117 774

John Kelly

Atomo Diagnostics

[john.kelly@atomodiagnostics.com](mailto:john.kelly@atomodiagnostics.com)

Phone: +61 401 922 279

*This announcement was authorised by John Kelly, Managing Director.*



### **About Atomo**

Atomo is an Australian medical device company supplying unique, integrated rapid diagnostic test (RDT) devices to the global diagnostic market. Atomo's patented devices simplify testing procedures and enhance usability for professional users and untrained self-testers. The Company has supply agreements in place for tests targeting infectious diseases including COVID-19, viral vs bacterial differentiation and female health. See more at [www.atomodiagnostics.com](http://www.atomodiagnostics.com).